Previously treated and treatment naïve pts with METmut aNSCLC were included and treated with crizotinib 250 mg BID until disease progression or intolerable toxicity….1 (4%) complete response (CR), 14 (58%) partial responses and 2 (8%) SDs ≥ 16 weeks were observed, with resulting OR-rate of 62% (95% CI, 41 – 81) and CB-rate of 71% (95% CI, 49 – 87). After 20.2 months median follow-up, median progression-free and overall survival were 8.3 (95% CI, 6.0 – NA) and 13.0 months (95% CI, 8.0 – NA), respectively....The pt who achieved CR had a TK domain mutation (p.H1094Y), all others exon 14 skipping METmuts.